ACT for ALS reauthorization was passed by Congress in September, and today, November 3, 2026, President Trump signed it, the final step to extending programs established by the original ACT for ALS through 2031, keeping the momentum moving toward a cure.
This victory belongs to the entire ALS community for its diligent work with partners on both sides of the aisle to shape and strengthen the bill, grounding it in what people living with ALS and families tell us every day: move faster, cut the barriers, and generate evidence that turns promising science into proven treatments.
The ACT for ALS Act (Accelerating Access to Critical Therapies for ALS Act) is a bipartisan federal law signed by President Joe Biden on Dec. 23, 2021. Its primary goal is to accelerate the development of treatments for amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, while expanding access to investigational therapies for people living with ALS.
The legislation is particularly important because ALS is a progressive, fatal neurodegenerative disease with limited treatment options. Many patients experience rapid disease progression and may not qualify for traditional clinical trials.
Learn more about the ACT for ALS and C-Path’s work in advancing treatments for those living with ALS and other rare and neurodegenerative diseases by visiting the Critical Path for Rare Neurodegenerative Diseases website here.
